MedPath

A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)

Phase 3
Completed
Conditions
Osteoporosis, Postmenopausal
Registration Number
NCT00092040
Lead Sponsor
Organon and Co
Brief Summary

The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
936
Inclusion Criteria
  • Postmenopausal women with osteoporosis
Exclusion Criteria
  • Any known allergy to the study drug

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Mean percent change from baseline in hip trochanter bone mineral density (BMD)
Secondary Outcome Measures
NameTimeMethod
Mean percent change from baseline in PA lumbar spine, total hip, and femoral neck BMD
© Copyright 2025. All Rights Reserved by MedPath